Net Income (Loss) Attributable to Parent in USD of Inhibrx, Inc. from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inhibrx, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2019 to Q1 2024.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Mar 2024 was -$78.7M, a 60.9% decline year-over-year.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Mar 2024 was -$271M, a 66.5% decline year-over-year.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$241M, a 66.2% decline from 2022.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$145M, a 77.6% decline from 2021.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$81.8M, a 7.41% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Inhibrx, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$271M -$78.7M -$29.8M -60.9% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024
Q4 2023 -$241M -$93.6M -$52.7M -129% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024
Q3 2023 -$189M -$51.8M -$16.5M -46.6% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$172M -$47.1M -$9.32M -24.7% 01 Apr 2023 30 Jun 2023 10-Q 09 Nov 2023
Q1 2023 -$163M -$48.9M -$17.7M -56.5% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$145M -$40.9M -$19.7M -93.1% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024
Q3 2022 -$126M -$35.3M -$14.7M -71.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$111M -$37.7M -$17M -82.2% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$93.7M -$31.3M -$12M -62% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$81.8M -$21.2M -$3.54M -20.1% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023
Q3 2021 -$78.2M -$20.6M -$83K -0.41% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$78.1M -$20.7M -$2.83M -15.8% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$75.3M -$19.3M +$804K +4% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$76.1M -$17.6M -$1.34M -8.24% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 -$74.8M -$20.5M -$334K -1.66% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$74.4M -$17.9M -$6.8M -61.3% 01 Apr 2020 30 Jun 2020 10-Q 09 Nov 2021
Q1 2020 -$67.6M -$20.1M -$16.2M -422% 01 Jan 2020 31 Mar 2020 10-Q 09 Nov 2021
Q4 2019 -$51.4M -$16.3M 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021
Q3 2019 -$20.2M 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$11.1M 01 Apr 2019 30 Jun 2019 10-Q 13 Nov 2020
Q1 2019 -$3.85M 01 Jan 2019 31 Mar 2019 10-Q 13 Nov 2020

Inhibrx, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$241M -$96.1M -66.2% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024
2022 -$145M -$63.5M -77.6% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024
2021 -$81.8M -$5.64M -7.41% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023
2020 -$76.1M -$24.7M -48.1% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022
2019 -$51.4M 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.